ArticleCritical care (London, England)2006
Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study.
Article in Critical care (London, England), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis.Antimicrobial agents and chemotherapy · 2010Pooled it
- Management of pneumonia by the emergency radiologist.European journal of radiology open · 2026Article
- Ultrasensitive Label-Free Electrochemical Detection ofPolymers · 2026Article
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Risk factors for 30-Day mortality and the role of empirical therapy in Pseudomonas aeruginosa bloodstream infections.Infection · 2025Article
- Development of an antibody fused with an antimicrobial peptide targeting Pseudomonas aeruginosa: A new approach to prevent and treat bacterial infections.PLoS pathogens · 2023Article
- Article
- Bloodstream Infections Caused by Carbapenem-ResistantInfection and drug resistance · 2021Article
- Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem forJournal of clinical medicine · 2018Article
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Penicillin-Binding Protein 3 Is Essential for Growth of Pseudomonas aeruginosa.Antimicrobial agents and chemotherapy · 2017Article
- Article
- Virulence Gene Profiles of Multidrug-Resistant Pseudomonas aeruginosa Isolated From Iranian Hospital Infections.Iranian Red Crescent medical journal · 2014Article
- New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.Antimicrobial agents and chemotherapy · 2014Article
- HNP-3 enhanced the antimicrobial activity of CIP by promoting ATP efflux from P. aeruginosa cells.Molecular biology reports · 2011Article
- The characteristics of metallo-β-lactamase-producing gram-negative bacilli isolated from sputum and urine: a single center experience in Korea.Yonsei medical journal · 2011Article
- An evaluation of the Charlson co-morbidity score for predicting sepsis after elective major surgery.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2011Article
- The development of ciprofloxacin resistance in Pseudomonas aeruginosa involves multiple response stages and multiple proteins.Antimicrobial agents and chemotherapy · 2010Article
- The occurrence of multidrug-resistant Pseudomonas aeruginosa on hydrocarbon-contaminated sites.Microbial ecology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHospital-acquired pneumonia (HAP) due to Pseudomonas aeruginosa is associated with high mortality rates. The metallo-beta-lactamases (MBLs) are emerging enzymes that hydrolyze virtually all beta-lactams. We aimed to assess P. aeruginosa HAP mortality in a setting of high-rate MBL production
methodsA prospective cohort study was performed at two tertiary-care teaching hospitals. A logistic regression model was constructed to identify risk factors for 30-day mortality.
resultsOne-hundred and fifty patients with P. aeruginosa HAP were evaluated. The 30-day mortality was 37.3% (56 of 150): 57.1% (24 of 42) and 29.6% (32 of 108) for patients with HAP by MBL-producing P. aeruginosa and by non-MBL-producing P. aeruginosa, respectively (relative risk, 1.93; 95% confidence interval (CI), 1.30-2.85). The logistic regression model identified a higher Charlson comorbidity score (odds ratio, 1.21; 95% CI, 1.04-1.41), presentation with severe sepsis or septic shock (odds ratio, 3.17; 95% CI, 1.30-7.72), ventilator-associated pneumonia (odds ratio, 2.92; 95% CI, 1.18-7.21), and appropriate therapy (odds ratio, 0.24; 95% CI, 0.10-0.61) as independent factors for 30-day mortality. MBL production was not statistically significant in the final model.
conclusionMBL-producing P. aeruginosa HAP resulted in higher mortality rates, particularly in patients with ventilator-associated pneumonia, most probably related to the less frequent institution of appropriate antimicrobial therapy. Therapeutic approaches should be reviewed at institutions with a high prevalence of MBL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.